Back to News
Market Impact: 0.35
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Source: globenewswire.com
M&A & RestructuringHealthcare & BiotechProduct Launches
Axogen acquired NerveTape™, the first FDA-approved device for sutureless peripheral nerve repair. The acquisition expands Axogen's addressable market within its core focus areas and adds a differentiated, regulated product to its nerve-repair portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
AXGN0.85
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Instacart reportedly discussed selling itself with DoorDash and Uber
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic
- J&J prostate cancer drug shows promising tumor responses in early trial